Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer

Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). However, the landscape of MET-specific targeting agents remains underdeveloped and understanding of mechanisms of resistance...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Bahcall, Magda, Sim, Taebo, Paweletz, Cloud P., Patel, Jyoti D., Alden, Ryan S., Kuang, Yanan, Sacher, Adrian G., Kim, Nam Doo, Lydon, Christine A., Awad, Mark M., Jaklitsch, Michael T., Sholl, Lynette M., Jänne, Pasi A., Oxnard, Geoffrey R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5140694/
https://ncbi.nlm.nih.gov/pubmed/27694386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0686
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi